Abstract
Cysteine proteases are one of the largest groups of proteases and are involved in many important biological functions in all kingdoms of life. They are virulence factors of a range of eukaryotic, bacterial and viral pathogens and are involved in host invasion, pathogen replication and disruption of the host immune response. Their activity is regulated by a range of protease inhibitors. This review discusses the various families of cysteine protease inhibitors, their different modes of inhibition and their evolutionary relationships. These inhibitors as well as the recent discovery of propeptide and propeptide-like inhibitors provide insights into the structures that are important for particular inhibitory mechanisms, thus forming the foundation for the design of future therapeutics.
Keywords: Cysteine proteases, cysteine protease inhibitors, therapeutics, infectious diseases, pathogen replication, immune response, evolutionary relationships, substrate specificity, nutrient acquisition, non-structural viral protein, Trypanosoma cruzi, Trypanosoma brucei, stefins, phytocystatins, factor aplha, interferon-γ-activated macrophages, nitric oxide, interleukin-10, β-immunoglobulin, proteolysis, BCPI
Current Protein & Peptide Science
Title: Cysteine Protease Inhibitors: from Evolutionary Relationships to Modern Chemotherapeutic Design for the Treatment of Infectious Diseases
Volume: 11 Issue: 8
Author(s): E. C.Y. Toh, N. L. Huq, S. G. Dashper and E. C. Reynolds
Affiliation:
Keywords: Cysteine proteases, cysteine protease inhibitors, therapeutics, infectious diseases, pathogen replication, immune response, evolutionary relationships, substrate specificity, nutrient acquisition, non-structural viral protein, Trypanosoma cruzi, Trypanosoma brucei, stefins, phytocystatins, factor aplha, interferon-γ-activated macrophages, nitric oxide, interleukin-10, β-immunoglobulin, proteolysis, BCPI
Abstract: Cysteine proteases are one of the largest groups of proteases and are involved in many important biological functions in all kingdoms of life. They are virulence factors of a range of eukaryotic, bacterial and viral pathogens and are involved in host invasion, pathogen replication and disruption of the host immune response. Their activity is regulated by a range of protease inhibitors. This review discusses the various families of cysteine protease inhibitors, their different modes of inhibition and their evolutionary relationships. These inhibitors as well as the recent discovery of propeptide and propeptide-like inhibitors provide insights into the structures that are important for particular inhibitory mechanisms, thus forming the foundation for the design of future therapeutics.
Export Options
About this article
Cite this article as:
C.Y. Toh E., L. Huq N., G. Dashper S. and C. Reynolds E., Cysteine Protease Inhibitors: from Evolutionary Relationships to Modern Chemotherapeutic Design for the Treatment of Infectious Diseases, Current Protein & Peptide Science 2010; 11 (8) . https://dx.doi.org/10.2174/138920310794557646
DOI https://dx.doi.org/10.2174/138920310794557646 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pyridine Based Antitumour Compounds Acting at the Colchicine Site
Current Medicinal Chemistry CYP24A1 as a Potential Target for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry E2F1 and NF-κB: Key Mediators of Inflammation-associated Cancers and Potential Therapeutic Targets
Current Cancer Drug Targets Evolution of Ipsilateral Head and Neck Radiotherapy
Current Cancer Therapy Reviews Management of Inflammatory Bowel Disease Patients with a Cancer History
Current Drug Targets Personalization of Targeted Therapy in Advanced Thyroid Cancer
Current Genomics The VHL Tumor Suppressor: Master Regulator of HIF
Current Pharmaceutical Design Genistein Down-Regulates miR-223 Expression in Pancreatic Cancer Cells
Current Drug Targets Intraorganellar Acidification by V-ATPases: A Target in Cell Proliferation and Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Approaches for the Treatment of Epidermal Growth Factor Receptor Mutated Lung Cancer
Current Cancer Drug Targets Elevated O-GlcNAcylation Promotes Malignant Phenotypes of Hypopharyngeal Squamous Cell Carcinoma by Stabilizing Nrf2 through Regulation of the PI3K/Akt Pathway
Anti-Cancer Agents in Medicinal Chemistry The Use of DNA Microarrays to Investigate the Pharmacogenomics of Drug Response in Living Systems
Current Topics in Medicinal Chemistry The Potential and Rationale for COX-2 Inhibitors in Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Inhibitors of the Immunoproteasome: Current Status and Future Directions
Current Pharmaceutical Design HSV-1-Derived Recombinant and Amplicon Vectors for Gene Transfer and Gene Therapy
Current Gene Therapy Lipoxygenase Inhibitors for Cancer Prevention: Promises and Risks
Current Pharmaceutical Design The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy
Current Drug Metabolism Cancer Gene Therapy by Adenovirus-Mediated Gene Transfer
Current Gene Therapy How Much of the Proteome Do We See with Discovery-Based Proteomics Methods and How Much Do We Need to See?
Current Proteomics In Silico Studies towards Enhancing the Anticancer Activity of Phytochemical Phloretin Against Cancer Drug Targets
Current Drug Therapy